DE602006019262D1 - QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN - Google Patents

QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN

Info

Publication number
DE602006019262D1
DE602006019262D1 DE602006019262T DE602006019262T DE602006019262D1 DE 602006019262 D1 DE602006019262 D1 DE 602006019262D1 DE 602006019262 T DE602006019262 T DE 602006019262T DE 602006019262 T DE602006019262 T DE 602006019262T DE 602006019262 D1 DE602006019262 D1 DE 602006019262D1
Authority
DE
Germany
Prior art keywords
beta
body fluids
pdgfr
diseases
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006019262T
Other languages
English (en)
Inventor
Peter J Hamer
Walter P Carney
Leticia Morris
James Elting
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics Inc
Original Assignee
Siemens Healthcare Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Healthcare Diagnostics Inc filed Critical Siemens Healthcare Diagnostics Inc
Publication of DE602006019262D1 publication Critical patent/DE602006019262D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/49—Platelet-derived growth factor [PDGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
DE602006019262T 2005-08-11 2006-08-10 QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN Active DE602006019262D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70780605P 2005-08-11 2005-08-11
PCT/US2006/031245 WO2007021860A2 (en) 2005-08-11 2006-08-10 QUANTITATIVE ASSAYS FOR PDGFR-β IN BODY FLUIDS

Publications (1)

Publication Number Publication Date
DE602006019262D1 true DE602006019262D1 (de) 2011-02-10

Family

ID=37758168

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006019262T Active DE602006019262D1 (de) 2005-08-11 2006-08-10 QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN

Country Status (5)

Country Link
US (1) US20070037224A1 (de)
EP (1) EP1913391B1 (de)
AT (1) ATE493652T1 (de)
DE (1) DE602006019262D1 (de)
WO (1) WO2007021860A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE556713T1 (de) * 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
EP2324825A1 (de) * 2002-02-11 2011-05-25 Bayer Healthcare LLC Arylharnstoffe mit Angiogenese hemmender Aktivität
NZ562414A (en) * 2003-02-21 2009-02-28 Resmed Ltd Headgear assembly for nasal pillow mask
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
US7191068B2 (en) * 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
US8068990B2 (en) * 2003-03-25 2011-11-29 Hologic, Inc. Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids
PT1626714E (pt) * 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
BRPI0617488A2 (pt) * 2005-10-21 2011-07-26 Bayer Healthcare Llc mÉtodo para a monitoraÇço do estado de uma doenÇa associada a uma via de vegf-165 ativada por ultra-expressço ou por mutaÇço de proteÍna vegf-165 em um paciente, mÉtodo de seleÇço de terapia para um paciente humano com uma doenÇa e mÉtodo de dignàstico para detectar uma doenÇa associada a uma via de vegf-165 ativada por ultra-expressço ou por mutaÇço de proteÍna vegf-165 em um paciente
KR20170091174A (ko) * 2007-04-03 2017-08-08 옥시레인 유케이 리미티드 분자의 글리코실화
WO2009137666A2 (en) * 2008-05-08 2009-11-12 The Trustees Of The University Of Pennsylvania Chemiluminescence enhanced detection
US20100004306A1 (en) * 2008-06-18 2010-01-07 Abbott Laboratories PIGF-1 Assay and kits and components thereof
WO2009155381A1 (en) * 2008-06-18 2009-12-23 Abbott Laboratories P/gf-1 companion diagnostic methods and products
US8741287B2 (en) * 2008-06-18 2014-06-03 Abbott Laboratories PlGF-1 assay and kits and components thereof
AU2009291203B2 (en) * 2008-09-10 2015-01-22 Life & Brain Gmbh Peripheral zone tumor cells, methods for their preparation and use
WO2010106140A1 (en) 2009-03-19 2010-09-23 Universite D'angers Non-invasive method for assessing liver fibrosis progression
CN102445543B (zh) * 2010-10-08 2014-03-12 中国医学科学院肿瘤研究所 辅助诊断肺癌淋巴结转移的试剂
GB201204014D0 (en) * 2012-03-07 2012-04-18 Univ Leeds Diagnostic marker compounds and their use
EP2972376B1 (de) * 2013-03-15 2018-12-05 Eisai Inc. Verfahren zur bestimmung der prognose von kolorektalkarzinom
KR102200344B1 (ko) 2013-04-25 2021-01-11 씨비에스바이오사이언스 주식회사 간세포 종양에 있어서 분자-표적 치료의 감수성을 증가시키기 위한 분석방법
EP3491388B1 (de) 2016-08-01 2021-09-01 Centre Hospitalier Universitaire d'Angers Multi-zielgerichteten fibrosetests
WO2020099487A1 (en) * 2018-11-14 2020-05-22 Vrije Universiteit Brussel Soluble pdgfrbeta as a biomarker for fibrosis
KR102363980B1 (ko) * 2020-04-13 2022-02-15 전남대학교산학협력단 전이성 뇌종양의 진단 또는 예후 분석용 바이오마커 및 이를 이용한 진단방법
JP2024511358A (ja) * 2021-03-19 2024-03-13 イーライ リリー アンド カンパニー ＰＤＧＦＲα阻害剤でがんを治療する方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745181A (en) 1986-10-06 1988-05-17 Ciba Corning Diagnostics Corp. Polysubstituted aryl acridinium esters
US6043211A (en) * 1988-02-02 2000-03-28 The Regents Of The University Of California Method for inhibiting the activity of a platelet-derived growth factor receptor binding protein
US6110737A (en) * 1988-02-02 2000-08-29 The Regents Of The University Of California Human platelet-derived growth factor receptor, type A
US6228600B1 (en) * 1992-07-20 2001-05-08 The United States Of America As Represented By The Department Of Health And Human Services Immunoassays for the alpha platelet-derived growth factor receptor
US5468468A (en) * 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
WO1990010013A1 (en) * 1989-02-09 1990-09-07 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce TYPE oc PLATELET-DERIVED GROWTH FACTOR RECEPTOR GENE
DK0474744T3 (da) * 1989-05-22 1994-11-21 Zymogenetics Inc PDGF-alfa-receptor
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5817310A (en) * 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5395752A (en) 1993-03-19 1995-03-07 Ciba Corning Diagnostics Corp. Long emission wavelength chemiluminescent compounds and their use in test assays
US6264949B1 (en) * 1998-09-29 2001-07-24 Mount Sinai School Of Medicine Of New York University Noninvasive agents for diagnosis and prognosis of the progression of fibrosis
DE60329020D1 (de) * 2002-03-01 2009-10-08 Siemens Healthcare Diagnostics Assays zur überwachung von krebspatienten auf grundlage der spiegel des analyten für die extrazelluläre domäne (ecd) des epidermalen wachstumsfaktor-rezeptors (egfr), allein oder in kombination mit anderen analyten, in proben von körperflüssigkeiten
PT1626714E (pt) * 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
WO2005015236A2 (en) * 2003-07-18 2005-02-17 Roche Diagnostics Gmbh A method for predicting the progression of adenocarcinoma

Also Published As

Publication number Publication date
WO2007021860B1 (en) 2008-02-28
US20070037224A1 (en) 2007-02-15
EP1913391A2 (de) 2008-04-23
WO2007021860A3 (en) 2007-10-04
EP1913391B1 (de) 2010-12-29
EP1913391A4 (de) 2009-02-18
WO2007021860A2 (en) 2007-02-22
ATE493652T1 (de) 2011-01-15

Similar Documents

Publication Publication Date Title
DE602006019262D1 (de) QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN
HK1183707A1 (en) Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease (pct)
DE602006018578D1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
CY1113403T1 (el) Νεος βιοδεικτης για την παρακολουθηση της εξελιξης των νοσων και την εκτιμηση της αποτελεσματικοτητας των θεραπειων
DK1421215T3 (da) Fremgangsmåder til evaluering af patologiske tilstande under anvendelse af ekstracellulært RNA
MX342791B (es) Ensayo elisa para la detección de vegf.
DE602006011896D1 (de) Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden
WO2009037454A3 (en) Cancer marker and therapeutic target
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
WO2007044860A3 (en) Diabetes-associated markers and methods of use thereof
BR112015011359A2 (pt) método para indicar uma presença ou não presença de câncer de próstata agressivo
BRPI0513692A (pt) marcadores de urina para detecção de cáncer de bexiga
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
BR112014019349A8 (pt) Previsão do resultado nos pacientes com doença pulmonar obstrutiva crônica
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
ATE459883T1 (de) Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose
ATE542139T1 (de) Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
Zhou et al. Increased levels of exhaled sICAM1, sVCAM1, and sE-selectin in patients with non-small cell lung cancer
WO2007080597A3 (en) Polynucleotide and polypeptide sequences and methods for diagnosis
ATE336506T1 (de) Verwendung löslicher cytokeratin-1-fragmente in diagnostik
DE602005025231D1 (de) Gene und polypeptide in verbindung mit brustkrebserkrankungen
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
DE602006015957D1 (de) Quantitative assays für ras p21 in körperflüssigkeiten
WO2023004079A3 (en) Compositions and methods for detection of liver cancer
CY1113290T1 (el) Μεθοδος για την ανιχνευση και διαγνωση καρκινου, η οποια περιλαμβανει εκκινητες και ανιχνευτες για την ειδικη ανιχνευση του δεικτη magε-a3